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Abstract
Background. Lymphopenia may lead to worse outcomes for glioblastoma patients. This study is a secondary analysis of the CCTG CE.6 trial evaluating the impact of chemotherapy and radiation on lymphopenia, and effects of
lymphopenia on overall survival (OS).
Methods. CCTG CE.6 randomized elderly glioblastoma patients (≥ 65 years) to short-course radiation alone (RT)
or short-course radiation with temozolomide (RT + TMZ). Lymphopenia (mild-moderate: grade 1–2; severe: grade
3–4) was defined per CTCAE v3.0, and measured at baseline, 1 week and 4 weeks post-RT. Preselected key factors for analysis included age, sex, ECOG, resection extent, MGMT methylation, Mini-Mental State Examination,
and steroid use. Multinomial logistic regression and multivariable Cox regression models were used to identify
lymphopenia-associated factors and association with survival.
Results. Five hundred and sixty-two patients were analyzed (281 RT vs 281 RT+TMZ). At baseline, both arms had similar
rates of mild-moderate (21.4% vs 21.4%) and severe (3.2% vs 2.9%) lymphopenia. However, at 4 weeks post-RT, RT+TMZ
was more likely to develop lymphopenia (mild-moderate: 27.9% vs 18.2%; severe: 9.3% vs 1.8%; p<0.001). Developing any
lymphopenia post-RT was associated with baseline lymphopenia (P < .001). Baseline lymphopenia (hazard ratio [HR] 1.3) was
associated with worse OS (HR: 1.30, 95% confidence interval [CI] 1.05–1.62; P = .02), regardless of MGMT status.
Conclusions. Development of post-RT lymphopenia is associated with addition of TMZ and baseline lymphopenia
and not with RT alone in patients treated with short-course radiation. However, regardless of MGMT status, only
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baseline lymphopenia is associated with worse OS, which may be considered as a prognostic biomarker for
elderly glioblastoma patients.

Key Points

• Development of lymphopenia is not associated with RT alone.
• Baseline lymphopenia is associated with worse OS.

Importance of the Study
This is a secondary analysis of CCTG CE.6 trial
evaluating the impact of lymphopenia with
overall survival in elderly patients with glioblastoma. The study demonstrated that the
hypofractionated radiation treatment regimen
used in the trial did not lead to development
of lymphopenia. Rather, development of postradiation lymphopenia was associated with
addition of TMZ and baseline lymphopenia.
Regardless of MGMT status, only baseline

Advancing the treatment paradigm for elderly glioblastoma
patients has been a complex balancing act between maximizing survival and aggressiveness of care. Compared to
best supportive care, adjuvant radiation therapy (RT) with
conventional fractionation (standard course) was shown
to nearly double median survival times (16.9 weeks vs
29.1 weeks) without compromising quality of life (QOL).1
Additional studies explored hypofractionation, with various shortened treatment schedules showing no difference
compared to outcomes with conventional fractionation.2,3
Temozolomide alone was found to be comparable for survival to standard course alone4 and hypofractionated radiation alone.5
Canadian Cancer Trials Group (CCTG) CE.6 (EORTC
26062-22061, TROG08.02) was a multi-institutional, openlabel randomized Phase III clinical trial investigating the
benefits of adding temozolomide to hypofractionated
(short course) RT for elderly (age ≥ 65 years) patients with
newly diagnosed glioblastoma.6 The authors reported both
an overall survival (OS) and progression-free survival (PFS)
benefit, with a more pronounced effect in patients with
methylated O6-methylguanine-DNA methyltransferase
(MGMT) status. There is concern, however, that the addition of temozolomide to radiation may lead to increased
incidence and severity of lymphopenia after concurrent
treatment has been completed.
Lymphopenia has been observed in glioblastoma patients receiving standard of care (SOC) chemoradiation,
with up to 40% developing grade 3 or higher adverse events.7 Temozolomide has demonstrated a

lymphopenia is associated with worse OS,
which may be considered as a prognostic biomarker for elderly glioblastoma patients.
This is the first study evaluated the incidence of treatment developed lymphopenia
with hypofractionated radiation with and
without temozolomide, as well as the impact
of lymphopenia on overall survival of elderly
patients with newly diagnosed glioblastoma
based on prospectively collected data.

dose-dependent toxicity for lymphopenia in glioblastoma.8 Glioblastoma patients are also oftentimes exposed to steroids, which also exhibit a dose-dependent
association with lymphopenia.9 Lymphopenia, particularly with a severe reduction in lymphocyte counts, has
been associated with worse survival outcomes, with a
hazard ratio (HR) of 1.8 for malignant gliomas receiving
SOC, resulting in a median OS difference of 16 versus
18 months.10 Elderly patients who are predisposed to
being immunocompromised11 may be at higher risk for
this phenomenon.
To date, there has not been an analysis of prospectively collected data to compare incidence and severity of
treatment-related lymphopenia (TRL) between the treatment arms of radiation alone (RT) versus radiation with
temozolomide (RT + TMZ). Based on these considerations,
we performed a secondary analysis of CCTG CE.6 to investigate the impact of concurrent chemoradiation versus RT
alone on the incidence and severity of lymphopenia in this
patient population and the potential association with survival outcomes.

Methods
This study was approved by the Institutional Review Board
at Thomas Jefferson University (Philadelphia, PA, USA).
The original study was registered on ClinicalTrials.gov
(Identifier: NCT00482677).
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562 Patients underwent randomization

281 Were assigned to radiotherapy + temozolomide
279 Were eligible to receive the intervention
2 Were not eligible
1 Was missing data on quality of life at baseline
1 Was eligible for full-course (6-wk) radiotherapy

4 Withdrew consent
1 Withdrew consent

281 Were included in the intentionto-treat analysis

281 Were included in the intentionto-treat analysis

10 Were excluded from
safety analysis
(not treated)

271 Were included in the safety analysis

10 Were excluded from
safety analysis
(not treated)

271 Were included in the safety analysis

Figure 1. CONSORT diagram from CCTG CE.6.
  

Patient Selection

Temozolomide

All eligible patients enrolled and randomized who received treatment in CCTG CE.6 from November 2007
to September 2013 were included in this analysis. See
CONSORT diagram from the original study in Figure 1.
Treatment details for each arm, for example, radiation
therapy and temozolomide dosing, are included in the original publication for reference.6 Patients who had evidence
of disease progression or died prior to the time of 4 weeks
after completion of RT, or missing hematology evaluation,
were excluded from the analysis of week 4 lymphopenia’s
status on PFS and OS.

Concurrent temozolomide was administered with radiotherapy at a dose of 75 mg per square meter of
body-surface area per day for 21 consecutive days
from day 1 until the final day of radiotherapy. Adjuvant
temozolomide was administered at a dose of 150–
200 mg per square meter per day for 5 consecutive days
of a 28-day cycle for up to 12 cycles or until disease
progression.

Radiation Treatment

Lymphopenia was defined per Common Terminology
Criteria for Adverse Events (CTCAE) v3.0 (US Department
of Health and Human Services, National Institutes of
Health, National Cancer Institute) by the following
grouping of grades12:

Short-course radiation was delivered as 40.05 Gy in 15
fractions over 3 weeks. A single planning target volume
(PTV) was derived from: (1) Gross tumor volume (GTV)
defined as the contrast-enhancing volume on the
postoperative planning magnetic resonance imaging
(MRI) scan including surgical bed, (2) Clinical target
volume (CTV) derived from GTV plus a 1.5-cm margin
respecting anatomical boundaries, and (3) PTV CTV
plus margin of 0.5 cm was applied. 3D planning techniques were utilized, while intensity-modulated radiation therapy was not permitted as specified per clinical
trial protocol.

Lymphopenia Analysis

1) Mild-moderate [Grade 1: <LLN × 0.8 – 109/L and Grade 2:
<0.8 – 0.5 × 109/L]
2) Severe [Grade 3: <0.5 – 0.2 × 109/L and Grade 4: <0.2 ×
109/L]
Lymphocyte counts were collected at baseline and
post-radiation, including at 1 week and 4 weeks after
completion.
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Statistical Analysis
Preselected key baseline patient characteristics for the
analysis included:

Chi-square test was used to assess association categorical variables; analysis of variance was used to test association of continuous factors with lymphopenia status;
Kaplan–Meier curves were used to estimate distributions
of the time to event outcomes. Landmark analysis was performed to study the association of week 4 lymphopenia’s
status on OS and PFS. Multinomial logistic regression
models were used to identify factors associated with
lymphopenia; and multivariable Cox regression models
were then used to study effects of lymphopenia across
time intervals on survival outcomes while adjusting baseline factors. All reported P values are 2 sided, and P value <
.05 was considered statistically significant. Analyses were
performed using SAS software (version 9.3; SAS Institute).

Tab

Early P/D

Non-Early
P/D

P-values

Age (years)

n (%)

n (%)

.10

65–70

27 (36.5)

138 (28.3)

71–75

22 (29.7)

209 (42.8)

76 and older

25 (33.8)

141 (28.9)

Female

28 (37.8)

191 (39.1)

Male

46 (62.2)

297 (60.9)

≤2

49 (66.2)

383 (78.5)

2

25 (33.8)

105 (21.5)

Biopsy only

35 (47.3)

131 (26.8)

Partial or complete

39 (52.7)

357 (73.2)

RT

41 (55.4)

240 (49.2)

RT+TMZ

33 (44.6)

248 (50.8)

Yes

63 (85.1)

360 (73.8)

No

11 (14.9)

128 (26.2)

Grade ≥ 1

26 (35.1)

178 (36.5)

Grade 0

48 (64.9)

310 (63.5)

Sex

.83

ECOG Performance

.02

Extent of Resection

<.01

Treatment Arm

.32

Steroids Use

.04

Lymphopenia (BL or 1W)

.82

MGMT methylation
status

Results
Patient Characteristics
There was a total of 562 patients, of which 281 were in the
RT alone arm and 281 received RT+TMZ. Of these, 74 patients (41 from RT and 33 from RT+TMZ) were excluded
from survival analysis due to early progression or death,
resulting in 488 patients (240 RT and 248 RT+TMZ). Patients
who had early progression or death were more likely to
have worse ECOG performance status (P = .02), biopsy
only (P < .001), steroid use (P = .04), and lower Mini-Mental
State Examination (MMSE) (P = .06).
Additional demographic and patient-related information
can be found in Table 1.

Lymphopenia Incidence and Severity
At baseline, lymphopenia rates were virtually identical between treatment arms, with approximately 75.6% of patients
with normal lymphocyte counts, 21.4% with mild-moderate
lymphopenia, and 3% with severe lymphopenia (Table 2). At
1-week post-RT, there was a small numerical increase in mildmoderate lymphopenia for patients on RT+TMZ (15.4% vs
10.7%), however, this was not statistically significant (P = .25).
At 4 weeks post-RT, there was a significant increase for both
incidence and severity of lymphopenia for patients who received RT+TMZ versus RT, with 37.2% versus 20%, of which

.33

Methylated

18 (24.3)

147 (30.1)

Un methylated

23 (31.1)

166 (34.0)

Unknown

33 (44.6)

175 (35.9)

Mean
(STD)

Mean (STD)

24.4 (5.6)

25.7 (4.4)

MMSE

.06

BL, baseline; 1W, lymphocyte count 1-week post-RT; P/D, progression
or death; STD, standard deviation.

  
9.3% versus 1.8% were Grade 3 or higher, respectively (P <
.0001). The rate of lymphopenia at 4 weeks post-RT is significantly higher than 1 week post-RT in the RT-TMZ group, but
not in the RT alone group.
At 4 weeks post-RT, factors associated with developing
lymphopenia included treatment arm RT+TMZ (OR 2.15;
95% CI 1.38–3.33; P = .0007) and lymphopenia present
at baseline (OR 5.12; 95% CI 3.30–7.94; P < .0001). These
factors were also associated with developing severe
lymphopenia, with RT+TMZ (OR 7.64; 95% CI 2.79–20.94;
P < .0001) and baseline lymphopenia (OR 9.01; 95% CI
−3.80–21.38; P < .0001), as well as biopsy only patients (OR
2.56; 95% CI 1.16–5.65; P = .02). Age, sex, ECOG, MGMT
status, steroid use at baseline, and MMSE were not found
to be associated with lymphopenia at 4 weeks post-RT in
multivariable analysis.
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a)	Age (65–70 years old; 71–75 years old; 76 years
and older)
b)
Sex (Male; Female)
c)
ECOG Performance Status (0 or 1; 2)
d)	Extent of resection (Biopsy only; partial or complete resection)
e)	MGMT promoter methylation status (Methylated;
Unmethylated)
f)
Mini-Mental State Exam (0–30)
g)
Steroid use at study randomization (Yes; No)
h)
Assigned treatment arm (RT; RT+TMZ)

  
Table 1. Patient Characteristics
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Table 2. Lymphopenia by Treatment Arms at Different Time Intervals
Treatment Arm

Lymphopenia at Baseline
Grades 1&2

212 (75.4%)

60 (21.4%)

Grades 3&4
9 (3.2%)

Total
281

RT + TMZ

213 (75.8%)

60 (21.4%)

8 (2.9%)

281

Treatment Arm

Lymphopenia at post-RT 1 week
Grade 0

Grades 1&2

Grades 3&4

Total

P-value

RT

238 (84.7%)

30 (10.7%)

13 (4.6%)

281

.25

RT + TMZ

224 (80.0%)

43 (15.4%)

13 (4.6%)

280

Treatment Arm

Lymphopenia at post-RT 4 weeks
Grades 3&4

Grade 0

Grades 1&2

Total

P-value

RT

225 (80.1%)

51 (18.2%)

5 (1.8%)

281

<.0001

RT + TMZ

176 (62.9%)

78 (27.9%)

26 (9.3%)

280

  
Impact on OS and PFS
OS was worse for patients who developed lymphopenia at
4 weeks post-RT (HR 1.29; 95% CI 1.04–1.60; P = .02) with
median OS of 7.95 months versus 9.92 months (Figure 2)
in landmark analysis. Comparison across lymphopenia severity did not yield statistically significant differences between mild-moderate versus severe lymphopenia (P = .07),
with median of OS of 7.92 versus 8.08 months, respectively.
However, after adjusting for confounding factors on
multivariable modeling, lymphopenia status at 4 weeks
post-RT was no longer associated with OS (P = .49), including for severe lymphopenia (P = .58). Instead, baseline
lymphopenia (HR 1.30; P = .02), males (HR 1.41), biopsy
only (HR 1.59), and lower MMSE (HR 0.975), were significantly associated with worse OS (Table 3).
Similarly, 4-weeks post-RT lymphopenia was significantly associated with PFS on univariate (HR 1.25;
P = .04), but not in multivariate analysis (P = .21). Baseline
lymphopenia was marginally significant for worse PFS (HR
1.22; P = .06), while male patients (HR 1.27; P = .01), biopsy
only (HR 1.33), and lower MMSE patients had significantly
worse PFS.
On the other hand, patients with baseline lymphopenia
have significantly worse OS (P = .0037, HR 1.341, 95% CI
1.099–1.637), and PFS (P = .0356, HR 1.235, 95% CI 1.013–
1.506). This remains significant after adjusting for confounding factors on multivariate modeling (Figure 2).

MGMT Promoter Methylation Status Stratification
When stratifying survival analysis by MGMT promoter
methylation status, baseline lymphopenia (HR 1.66;
P = .02), males (HR 1.45; P = .04), steroid use at baseline
(HR 1.84; P = .005) were significantly associated with worse
OS in MGMT methylated patients. Baseline lymphopenia
(HR 1.59; P = .004) and lower MMSE (HR 0.961; P = .05)
were significantly associated with worse OS in MGMT
unmethylated patients.
For PFS, MGMT methylated patients who were male
(HR1.61; P = .01) and steroid use (1.86; P = .005), had worse
outcomes. Baseline lymphopenia (HR 1.75; P = .003) and

worse ECOG (HR 1.65; P = .05) were associated with reduced PFS in MGMT unmethylated patients.

Discussion
Our study results confirm our hypothesis that the addition
of concurrent TMZ to RT results in not only increased incidence of treatment-related lymphopenia, but also increased severity. However, surprisingly, the severity and
incidence of 4 weeks post-RT lymphopenia did not impact OS or PFS, including on subgroup analysis by MGMT
methylation status. Instead, lymphopenia present at baseline of both mild-moderate and severe grades was significantly associated with OS for both MGMT methylated and
unmethylated patients.
Our study is unique as the largest reported for exploring
lymphocyte counts in glioblastoma patients from a prospectively conducted investigation. With a 1:1 split between
treatment arms and all patients receiving short-course RT
by clinical trial design, this provides a well-controlled environment answering questions on how specific treatment
modalities may contribute to the incidence and severity
of lymphopenia, and more importantly the impact these
events may have on survival outcomes. Although our results may appear discordant with prior reports of smaller
studies in the GBM literature,10,13 we believe that our
finding on baseline lymphopenia as a prognostic factor
may, in a way, is in agreement.14–16 Previously reported literature has various definitions for baseline lymphopenia,
ranging from lymphocyte counts of 800/µL to 1000/µL and
1500/µL.10,17–19 Studies specifically addressing this question
are limited, with one publication from the literature addressing lymphopenia in elderly GBM, however, this was a
retrospective study of 72 patients, of which just 20 patients
(30.56%) received short-course RT.14 Thus, our study provides a unique prospective outlook on elderly GBM which
typically has less aggressive RT and concurrent phase
therapy.
Lymphopenia rates reported previously in primary as par
for hematologic toxicity, but not stratified by timepoints
and not statistically analyzed for significance between
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100
4 weeks Post RT

Lymphopenia grade > 0

60

40

20

0
4

8

12

16

20

24

28

32

36

40

44

48

52

56

G = 0 368

327

224

125

76

48

25

15

9

8

8

4

2

1

0

0

G > 0 120

104

59

36

23

14

7

3

1

0

0

0

0

0

0

6
3
Time (months)

60

B
100

Baseline lymphopenia

80

Lymphopenia grade 0

Lymphopenia grade > 0

Stratified log rank test: p = 0.0037

60

40

20

0
0
G = 0 416
G > 0 135

4
340
97

8
226
56

12
123
31

16
73
16

20
43
8

24
20
1

28
10
0

32
1
0

36
0
0

40
0
0

Time (months)

Figure 2. Kaplan–Meier survival curves. (A) Overall survival for 4 weeks post-RT lymphopenia. (B) Overall survival worse with baseline
lymphopenia (Grade >0).
  

treatment arms.6 We showed that baseline lymphopenia
significantly increases the risk for developing treatmentrelated lymphopenia, including severe lymphopenia.
Therefore, our analysis elucidated an additional facet on
the importance of timepoint for lymphopenia, especially at
baseline for elderly GBM patients, which had not been previously reported.
Baseline lymphopenia may represent several pretreatment concerns for patients. First, this may serve as a surrogate for poor reserve or immunocompromised patients.
Second, this may represent a secondary lymphotoxic

effect from steroid exposure prior to trial randomization,
which may indicate patients with more clinical symptoms,
extensive disease burden, and/or unresectable disease.
Analysis on patients enrolled on EORTC trials with breast,
non-Hodgkin’s lymphoma, and soft tissue sarcoma patients also showed pretreatment lymphocyte count less
than 1000/mm3 was associated with higher risk of death.18
In GBM patients, pretreatment lymphopenia is associated
with post radiation treatment lymphopenia,19 which is
consistent with our finding. However, caution should be
given for GBM patients with pretreatment lymphopenia
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Factors

HR (95% CI)

W4 Lymphopenia

P-value
.77

1.09 (0.83, 1.41)

.54

Grade 3 or 4

1.14 (0.71, 1.84)

.58

Grade 0

1

Baseline Lymphopenia
Grade 1+

1.30 (1.05, 1.62)

Grade 0

1

.02

Keywords
elderly | glioblastoma | lymphopenia | short-course radiotherapy | temozolomide

Sex
Male

1.41 (1.16, 1.71)

Female

1

.0004

Funding
This research did not receive any specific grant from funding
agencies in the public, commercial, or not-for-profit sectors. The
authors would like to Ms. Peggy Grove for philanthropic support
for this study.

Extent of Resection
Biopsy only

1.59 (1.29, 1.96)

Partial or complete resection

1

<.0001

Steroids use
Yes

1.16 (0.93–1.44)

No

1

.18

Authorship Statement. Conception design and development:
A.J.S., W.S. Statistics: K.D. Writing and revision of manuscript:
A.J.S., W.S. Revision and final approval of manuscript: A.J.S.,
A.D., I.A., N.J.L., J.P., W.P.M., C.W., C.J.O., J.J.M., A.A.B., C.P.,
M.F.F., R.N., D.O., J.G.C., W.R., W.W., W.S.

ECOG PS
2

1.14 (0.89–1.45)

0 or 1

1

MMSE

0.976 (0.955–0.997)

.31
.02

CI, confidence interval; HR, hazard ratio; OS, overall survival.

  
may be due to more extensive tumor and/or dependance
of steroids, which may be associated with worse outcome.
Although we controlled for steroid exposure at baseline,
information regarding the length of exposure and dosing
of steroids was not collected. Further study is needed to
better understand the impact of steroids on GBM patients’
treatment outcomes.
Radiation treatment plan dosimetry has been shown to
predict the risk of lymphopenia, and V25 of brain tissue less
than 56% with conventional fractionation regimen may
reduce the risk of severe lymphopenia.20 Despite the unavailability of detailed dosimetric data on radiation treatment plans in this study, our results show no significant
lymphopenia attributable to radiation treatment alone.
This may be due to the radiation target volume, and dose
fractionation scheduled. Radiation volume is based on residual enhancing tumor and resection cavity, as well as
encompassing FLAIR abnormalities. The hypofractionation
radiation regimen used in the current trial may further reduce the risk of radiation induced lymphopenia. Based
on the estimated probability of circulating lymphocytes
through the radiation fields during treatment, the magnitude of radiation exposure and its impact is greatly reduced with hypofractionation.7,21
Our current analysis showed short-course RT alone does
not lead to lympohpenia after treatment. Development
of lymphopenia post-RT is associated with addition of
TMZ and baseline lymphopenia. However, only baseline
lymphopenia is associated with worse OS regardless of
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